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Abstract
Background: Early antiretroviral therapy (ART) initiation in patients diagnosed with HIV-associated tuberculosis (TB) reduces
mortality among those with the lowest CD4 counts. At the same time, both early ART and a low CD4 count heighten the risk of
paradoxical TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). TB is common in patients starting ART
in sub-Saharan Africa. Safe interventions that reduce the incidence or severity of TB-IRIS are needed. Prednisone has been shown
to reduce symptoms and markers of inflammation when used to treat TB-IRIS.
Objective: To determine whether prophylactic prednisone in patients at high risk for paradoxical TB-IRIS initiating ART reduces
the incidence of TB-IRIS.
Methods: We are conducting a randomized, double-blind, placebo-controlled trial of prophylactic prednisone (40 mg/day for
2 weeks, followed by 20 mg/day for 2 weeks) initiated at the same time as ART in patients at high risk for TB-IRIS (starting
ART within 30 days of TB treatment and CD4 count ≤100/μL). The primary endpoint is development of TB-IRIS, defined using
an international consensus case definition. Secondary endpoints include time to TB-IRIS event, severity of TB-IRIS, quality of
life, mortality, hospitalization, other infections and malignancies, and adverse events including corticosteroid adverse effects.
Results: Enrollment for the trial began in August 2013. All 240 participants have been enrolled, and safety follow-up will be
completed in March 2017.
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Conclusion: No preventive strategies for TB-IRIS currently exist. If results of this trial demonstrate the efficacy and safety of
prednisone, this will provide clinicians with an evidence-based preventive strategy in patients at high risk for paradoxical TB-IRIS
when initiating ART.
(JMIR Res Protoc 2016;5(3):e173)   doi:10.2196/resprot.6046
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Introduction
Overview
Tuberculosis (TB) is the most common opportunistic disease
affecting HIV-1-infected patients in low- and middle-income
countries; up to 42% of patients starting antiretroviral therapy
(ART) in sub-Saharan Africa are on treatment for active TB
[1]. When ART is commenced in patients on treatment for active
TB, an immunopathological reaction known as paradoxical
TB-associated immune reconstitution inflammatory syndrome
(TB-IRIS) is reported in 18% of cases (95% CI 16%-21%),
resulting in new or recurrent TB-related signs and symptoms.
The most common clinical features are (1) pulmonary features
such as recurrent cough, chest pain, and worsening radiographic
pulmonary infiltrates and (2) inflammation and enlargment of
lymph nodes. Although mortality attributed to TB-IRIS is
relatively low (2%, 95% CI 1%-3%), TB-IRIS causes
considerable morbidity, with 25% (95% CI 19%-30%) of cases
requiring hospitalization [2]. Neurological involvement, less
frequent than pulmonary and nodal involvement, is associated
with substantial mortality [3].
Several clinical trials have evaluated the optimal timing of ART
initiation in ART-naïve HIV-infected patients diagnosed with
active TB. These were included in a recent meta-analysis which
showed that early ART (around 2 weeks into TB treatment) in
patients with CD4 counts ≤50/μL improved survival compared
with starting at around 8 weeks [4]. However, low CD4 count
and shorter interval between TB treatment and ART are two of
the most important risk factors for TB-IRIS [2]. The same
meta-analysis showed that early ART more than doubled the
risk of TB-IRIS. In patients with a CD4 count <50/μL, the risk
of TB-IRIS with early ART is particularly high [5,6]. Thus,
while international guidelines now advise ART within 2 weeks
in TB patients with CD4 <50/μL, it can be anticipated that this
will increase the risk of TB-IRIS. Despite this, no
evidence-based strategy for preventing TB-IRIS currently exists.
TB-IRIS will continue to be a major complicating factor in ART
programs in sub-Saharan Africa, even with the new World
Health Organization guidelines recommending to start ART in
all newly diagnosed HIV-infected patients regardless of CD4
count [7], because many HIV-infected individuals still enter
care with low CD4 counts and active TB [8-10]. Therefore,
interventions to reduce the incidence of TB-IRIS are urgently
needed. TB-IRIS is thought to result from an exaggerated
immune response in the context of rapidly recovering immunity
in the presence of abundant Mycobacterium tuberculosis antigen
at sites of disease. Attenuating this aberrant inflammatory
response during early ART with corticosteroids may prevent
TB-IRIS or at least reduce the severity of TB-IRIS clinical
manifestations.
Corticosteroids in the Treatment of Tuberculosis
The host immune response contributes to pathology caused by
TB [11], and corticosteroids have been used as adjunctive
treatment in TB for several decades [12]. Corticosteroid
treatment does not diminish the efficacy of TB treatment [12].
Evidence of significant clinical benefit from controlled clinical
trials exists for treatment of TB meningitis, where it reduced
short- to medium-term mortality [13,14], and pericardial TB,
where it reduced the complication of constriction [15], as well
as in the treatment of paradoxical TB-IRIS [16].
A Cochrane systematic review of corticosteroids as an adjunct
to TB treatment in TB meningitis showed that corticosteroids
reduced the risk of death (relative risk 0.78, 95% CI 0.67-0.91).
The survival benefit occurred irrespective of the severity of TB
meningitis [13]. One of the studies included in the review also
demonstrated significantly fewer severe adverse events in
patients who received dexamethasone [17]. In particular, eight
cases of severe drug-induced hepatitis occurred in the placebo
group and none in the dexamethasone group. Adverse drug
reactions are another major complicating factor in the
management of HIV-associated TB. By reducing the incidence
of these hypersensitivity reactions, corticosteroids could
potentially reduce morbidity, mortality, and the burden on
limited health care resources.
The Investigation of the Management of Pericarditis (IMPI)
trial was conducted in several African countries and evaluated
prednisolone (and M indicus pranii in a factorial design) in 1400
patients with tuberculous pericarditis, of whom 67% were
HIV-infected [15]. Participants were assigned to receive either
prednisolone or placebo for a period of 6 weeks. The primary
outcome was a composite of death, the first occurrence of
cardiac tamponade requiring pericardiocentesis, or constrictive
pericarditis. There was no significant difference in the primary
outcome between patients who received prednisolone and those
who received placebo. Prednisolone therapy, however, was
associated with significant reductions in the incidence of
constrictive pericarditis and hospitalization, which were
secondary endpoints.
In the IMPI trial, prednisolone was associated with an increase
in cancers (1.8% vs 0.6%, P=.03). These were mainly
HIV-related cancers, and most patients who developed HIV
cancers were not taking ART at the time of enrollment to the
trial (personal communication, IMPI investigators). These
findings added to concerns regarding the use of adjuvant
corticosteroids in HIV-infected patients present from two prior
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trials conducted in Uganda evaluating prednisolone in
HIV-associated TB, both conducted prior to ART availability.
One showed that prednisolone was associated with more rapid
clinical and radiological improvement but also with an excess
of Kaposi sarcoma [18]; the other showed more rapid clearance
of M tuberculosis from sputum with prednisolone treatment but
also a transient increase in HIV viral load (as well as worsening
of underlying hypertension, fluid retention, and hyperglycemia)
[19]. A third trial in Zambia showed more reactivation of herpes
zoster during prednisolone use in HIV-associated TB [20].
Corticosteroids in the Treatment of
Tuberculosis-Associated Immune Reconstitution
Inflammatory Syndrome
We previously conducted a randomized double-blind
placebo-controlled trial of prednisone for the treatment of
paradoxical TB-IRIS [16]. A 4-week course of prednisone (1.5
mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks)
resulted in significantly reduced hospitalization and need for
outpatient therapeutic procedures, and more rapid clinical
improvement. There was no excess of corticosteroid metabolic
adverse effects or severe infections in the prednisone arm.
Significant decreases in the serum concentrations of interleukin
6, interleukin 10, interleukin 12p40, tumor necrosis factor α,
interferon γ, and interferon γ-inducible protein 10 on prednisone
suggest that the beneficial effect of corticosteroids in TB-IRIS
was mediated at least in part through the attenuation of
proinflammatory cytokine responses [21]. We have previously
demonstrated that these same cytokines are differentially
increased in the serum of HIV-associated TB patients who
develop TB-IRIS compared to control subjects who start ART
and do not [22].
In HIV-infected patients with pneumocystis pneumonia, early
adjunctive treatment with corticosteroids reduces mortality and
the risk of mechanical ventilation. It is presumed that as
organisms are killed, inflammation increases in the lungs,
leading to a worsening of the patient’s clinical condition;
corticosteroids possibly reduce or prevent this worsening by
reducing inflammation [23].
We are currently conducting a randomized controlled trial (the
PredART trial) in Khayelitsha, South Africa, with the primary
objective to determine whether a 4-week course of prednisone
in patients at high risk for TB-IRIS (starting ART within 30
days of starting treatment for TB and a CD4 count of ≤100/μL)
reduces the incidence of TB-IRIS. This PredART trial is
different to our prior treatment trial [16] in that prednisone is
being evaluated as a preventive rather than treatment strategy
and given at lower doses.
Among the secondary objectives, we aim to determine whether
prednisone reduces the severity of TB-IRIS and the risk of
hypersensitivity drug reactions and consequent drug
interruptions in this group of patients as well as to assess its
safety and potential changes in health-related quality of life
(HR-QOL).
In summary, TB-IRIS is a common complication of ART in
patients with HIV-associated TB. The risk of TB-IRIS is highest
in patients with the lowest CD4 counts; rapid ART initiation in
such patients (essential because of the proven survival benefit)
increases this risk even further. Immunological studies have
shown elevation of a range of proinflammatory cytokines at the
time of TB-IRIS onset [22,24-26]. Corticosteroids have proven
to be beneficial in the treatment of TB-IRIS. This effect is likely
due at least partially to reductions in blood concentrations of
key cytokines mediating the condition. We are therefore
evaluating whether prednisone could also be beneficial in
preventing TB-IRIS. Because in the majority of cases the onset
of TB-IRIS is within the first 4 weeks of ART [27], prophylactic
interventions may only be required for one month. Adjunctive
corticosteroids in these profoundly immunosuppressed patients
might not be without risk; they have been shown to increase the
risk of Kaposi sarcoma and herpes reactivations [15,18-20],
mainly in patients not on ART. All patients in our trial are
receiving ART, which is likely to be at least partially protective
against these adverse effects.
Methods
Study Design
This is a proof-of-concept, phase III, randomized, double-blind,
placebo-controlled trial of prednisone to assess its efficacy and
safety in preventing paradoxical TB-IRIS in high-risk patients
starting ART. The intervention is oral prednisone 40 mg daily
for 14 days started within 48 hours of initiating ART, followed
by 20 mg daily for 14 days. Based on the average weight of
participants, this is a lower dose than was used in our previous
TB-IRIS prednisone treatment trial [16]. Our reasoning was
that when using prednisone as prophylaxis (rather than as
antiinflammatory treatment), a lower dose would be potentially
effective with a lower risk for adverse events. In our decision
regarding the prednisone dose for this trial, we factored in that
rifampicin increases the clearance of prednisolone by 45% [28].
Sample Size Calculation
The incidence of paradoxical TB-IRIS in patients on TB
treatment starting ART varies between 0% and 54% in the
literature. In a recent meta-analysis, the pooled estimate was
18% (95% CI 16%-21%) [2]. However, the incidence is
substantially higher in patients with a CD4 count ≤100/μL
starting ART within 30 days of TB treatment because these are
two major risk factors [2,29]. Assuming 35% cumulative
incidence of TB-IRIS in the placebo arm and a 50% relative
reduction in the prednisone arm and requiring 80% power to
test for the difference in TB-IRIS at a 2-sided significance level
of 5%, the sample size required was 110 in each arm. We
therefore aimed to recruit 240 participants, assuming loss to
follow-up of 10%.
Allocation
Blinded medication containers were packaged at an independent
off-site pharmacy in a 1:1 randomization sequence with block
sizes of 8. The sequence was prepared before the trial started
by an independent statistician. The packages contain either
prednisone 5 mg or identical placebo tablets. Each package has
a number from 1 to 240. Participants are enrolled sequentially
and receive the next study number from 1 to 240 with the
corresponding medication package. Participants and all study
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staff remain blinded to the treatment allocation throughout the
course of the trial. When deemed essential for ongoing clinical
management by the attending clinician, unblinding of the
randomization allocation can occur.
Setting, Selection, and Enrollment of Participants
Participants are recruited from four different TB clinics in
Khayelitsha, a township 20 kilometers from Cape Town’s center
with an estimated 500,000 inhabitants. An estimated 16% of
the population is HIV infected [30]; TB case notification is
917/100,000 per year and HIV coinfection among TB cases is
60% (City of Cape Town, 2015). The study team identifies
patients who could fulfill the enrollment criteria and invites
them to attend a screening visit. Informed consent is obtained
for the screening visit in the language of choice (mainly
isiXhosa), an information leaflet about the trial is provided and
discussed, and a screening visit is conducted. Patients who fulfill
enrollment criteria are invited to enroll in the trial. Detailed
information about the trial is provided by a member of the study
team, who also answers all questions the patient has before
enrollment. An enrollment informed consent form is signed if
the patient agrees to participate in the trial. In patients who are
unable to write, informed consent is taken in the presence of an
independent witness, who signs the informed consent document
next to the participant’s thumb print. Participation is voluntary
and patients can refuse participation or withdraw from the trial
at any time without compromising their standard medical care
(See Figure 1).
Figure 1. Flow of participants.
Inclusion and Exclusion Criteria
Inclusion and exclusion criteria are shown in Textbox 1.
Exclusion criteria include conditions where corticosteroid
treatment is recommended and conditions in which
corticosteroids are contraindicated or potentially harmful.
Patients should be receiving standard intensive-phase treatment
for drug-susceptible TB (rifampicin [RIF], isoniazid [INH],
pyrazinamide [PZA], and ethambutol [EMB]) when enrolled
in the trial.
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Textbox 1. Inclusion and exclusion criteria.
Inclusion criteria:
• Age 18 years or older
• HIV-infected
• CD4 count ≤100/μL (in the past 3 months)
• ART-naïve
• Confirmed diagnosis of TB or strong clinical and radiological evidence of TB with symptomatic response to TB treatment
• On TB treatment for less than 30 days prior to study entry
• Eligible for ART and patient consents to start ART within 30 days of starting TB treatment
• Written informed consent
Exclusion criteria:
• Kaposi sarcoma
• Pregnant
• TB meningitis or tuberculoma at TB diagnosis
• Clinical syndrome of pericardial TB at TB diagnosis
• Rifampicin-resistant TB
• On corticosteroids for another indication or on any other immunosuppressive medication within the past 7 days
• Uncontrolled diabetes mellitus
• Alanine aminotransferase >200 IU/L
• Absolute neutrophil count <500/μL
• Not on standard intensive-phase TB treatment
• Poor clinical response to TB treatment prior to ART as judged by the clinical investigators
• Hepatitis B surface antigen positive
Study Endpoints
The primary endpoint is the development of paradoxical
TB-IRIS within 12 weeks of starting ART, defined using the
International Network for the Study of HIV-associated IRIS
(INSHI) consensus case definition [31]. Secondary endpoints
are divided into efficacy and safety and tolerability endpoints
(Textbox 2).
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Textbox 2. Secondary endpoints.
Secondary efficacy endpoints:
• Time to TB-IRIS event from start of ART
• Severity of TB-IRIS events (defined by need for hospitalization, neurological involvement, and C-reactive protein)
• Duration of TB-IRIS events
• Mortality attributed to TB and TB-IRIS
• All-cause mortality
• Composite endpoint of death, hospitalization, or hepatotoxicity
• Other (non-TB) IRIS events
• Health-related quality of life assessments using the Patient-Reported Outcomes Quality of Life–HIV (PROQOL-HIV) [32], an adaptation of the
HIV symptom index [33], and the EuroQol Five Dimensions Questionnaire (EQ-5D-3L) [34]
• Adverse events and severe adverse events ascribed to TB treatment, ART, or co-trimoxazole
• Discontinuation of ART or TB treatment for more than 5 days due to adverse events
• Number of hospitalizations and total days hospitalized
Secondary safety and tolerability endpoints:
• Corticosteroid-associated adverse events (predefined as hypertension, hyperglycemia, hypomania/mania, depression, acne, epigastric pain, upper
gastrointestinal bleeding, Cushingoid features, new edema, and avascular bone necrosis)
• Laboratory safety data: glucose, full blood count, and electrolytes
• Other infections and malignancies
• All grade 1, 2, 3, and 4 adverse events using the Division Of AIDS Table For Grading the Severity of Adult and Pediatric Adverse Events [35]
Medication
Study medication is prednisone tablets (5 mg) or identical
placebo. The study medication was manufactured by the Gulf
Drug Company in Durban, South Africa; this company supplies
prednisone (Trolic) to the South African government hospital
pharmacies, and the product is registered with the Medicines
Control Council of South Africa. Participants receive 8 tablets
daily (40 mg prednisone or placebo) for 14 days followed by 4
tablets daily (20 mg prednisone or placebo) for 14 days. Study
medication is dispensed at week 0 (for the first 14 days) and at
week 2 (for the next 14 days). During these first four weeks of
the trial, concomitant treatment with nonsteroidal anti
inflammatory drugs, any systemic corticosteroid medication,
or any other immunosuppressive medication or chemotherapy
is prohibited. The protocol requires that the study drug be
stopped in the following situations: Kaposi sarcoma or new
World Health Organization stage 4 opportunistic condition
diagnosed, diagnosis of rifampicin-resistant TB, development
of TB-IRIS requiring open label prednisone, requirement for
prohibited concomitant medication, diagnosis of pregnancy,
request by the participant, clinical reasons believed to be life
threatening by the trial doctor, or interruption of ART or study
drug for more than five days by the participant or by clinician
(eg, in the event of ART toxicity).
ART is provided according to the South African Department
of Health guidelines [36]. First-line ART consists of tenofovir
(TDF) 300 mg daily, emtricitabine (FTC) 200 mg daily, and
efavirenz (EFV) 600 mg daily. In case of contraindications or
toxicity, TDF is substituted with abacavir (ABC) and EFV with
nevirapine or lopinavir boosted with ritonavir (LPV/r). LPV/r
is double-dosed in patients taking rifampicin [37]. ABC only
became available for use in the public sector during the course
of our trial. Before its availability, TDF was replaced with either
zidovudine or stavudine in the event of contraindication or
toxicity. The intensive follow-up period of the trial is 12 weeks;
no switches to ART for virological failure are made during this
period. Participants receive ART from their ART clinic in close
communication with the study team.
TB treatment is prescribed according to South African
Department of Health guidelines [38] by the participant’s TB
clinic. Participants receive weight-based daily doses of INH,
RIF, PZA, and EMB for 2 months, followed by INH and RIF
for another 4 months. If TB drug-induced liver injury occurs
during follow-up, participants are managed according to local
clinical guidelines. In short, TB treatment is stopped and
replaced with 3 drugs with no/low hepatotoxicity risk (eg, EMB,
kanamycin, and moxifloxacin). In addition, other possible
hepatotoxic drugs like co-trimoxazole and EFV may be
temporarily stopped or replaced. Once symptoms of hepatitis
have resolved and alanine aminotransferase is <100 IU/L, drugs
can be rechallenged one by one with close monitoring of liver
enzymes. Duration of TB treatment is individualized after
rechallenge. All participants are eligible for co-trimoxazole
prophylaxis unless contraindicated.
Schedule
Study visits occur at screening, enrollment, week 0 (the day the
participant starts study drug and ART), week 1, week 2, week
4, week 8, and week 12. A window period of 4 days is allowed
for each visit from week 1 to week 8; week 12 has a 7-day
window. Assessments done at each visit are summarized in
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Table 1. If the attending clinician suspects TB-IRIS, laboratory
investigations including a bacterial blood culture and a chest
radiograph are performed.
Outside the scheduled visits, participants can attend for
unscheduled visits if they experience symptomatic deterioration
or if deemed necessary by the attending clinician. For
participants with ongoing TB-IRIS at week 12, follow-up is
extended in order to ascertain the end date of TB-IRIS.
Table 1. Schedule of events.
Unscheduled visitWk 12Wk 8Wk 4Wk 2Wk 1Wk 0EnrollmentScreeningStudy visit
Not specified84±756±428±414±47±40Aim for −7 to 0Not specifiedARTa day
xDocument HIV status
xScreening ICFb
xEnrollment ICF
xxStudy drug
dispensed
xxxxxxxxxSymptomsc
xxxxxxxxKarnofsky score
xxxxxxPill countd
xxxHR-QOLe assessments
xxxxxxxIfxExamination
IxxxxIxLaboratory investiga-
tionsg
xxCD4 count, HIV viral
load
xSerum HBsAgh
xSerum CrAgi
IIIIIIIIxUrinary pregnancy test
If IRIS suspectedxxxxStorage bloods and im-
munology assays
If IRIS suspectedxxStorage urine
If IRIS suspectedxIChest radiograph
xxxSputum Xpert
MTB/RIFj, TB culture,
and DSTk
xInitiate ART
aART: antiretroviral therapy.
bICF: informed consent form.
cSymptoms and specific screening for adverse events and TB-IRIS.
dPill count: ART and study drug week 1-4.
eHR-QOL: health-related quality of life.
fI: if clinically indicated.
gLaboratory investigations: full blood count with leucocyte differentiation, sodium, potassium, creatinine, glucose, bilirubin, alanine aminotransferase,
alkaline phosphatase, C-reactive protein.
hHBsAg: hepatitis B surface antigen.
iCrAg: cryptococcal antigen.
jMTB/RIF: Mycobacterium tuberculosis, resistance to rifampicin.
kDST: drug sensitivity testing.
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Protocol Change With Additional Safety Assessments
In the initial protocol, participant follow-up ended at week 12
unless there was ongoing TB-IRIS at this visit. A year after the
start of our trial, the results of the IMPI trial [15] became
available, showing an increased incidence of cancer in patients
with HIV-related TB pericarditis prescribed prednisolone
compared to those prescribed placebo. This was largely
attributable to an increase in HIV-associated cancers (Kaposi
sarcoma and non-Hodgkin lymphoma). The potential risk of
Kaposi sarcoma associated with corticosteroid use in
HIV-infected patients was known and addressed in our protocol
prior to the IMPI publication: Kaposi sarcoma at screening is
an exclusion criterion, Kaposi sarcoma is ascertained as a safety
endpoint, and if Kaposi sarcoma occurs in patients on the trial
this is an indication to immediately stop study medication.
As a study team we reviewed the implications of the IMPI
findings for safety of participants in our trial. A number of
considerations make the IMPI trial different from the PredART
trial with respect to the risk of Kaposi sarcoma. The prednisone
dose used in PredART is substantially lower and of shorter
duration. All participants in the PredART trial are started on
ART when they start study medication, and ART is known to
reduce the risk of Kaposi sarcoma [39]; in contrast, in IMPI, 7
out of 9 of the prednisolone-treated patients who developed
HIV-related cancers were not on ART at the time of enrollment
and commencement of steroids (personal communication, IMPI
investigators). Lastly, the PredART trial participants are not
being randomized to M indicus pranii; this is relevant, as most
of the cancers were diagnosed in participants receiving both
prednisolone and M indicus pranii in the IMPI trial.
At the time of the IMPI publication, 89 participants had been
randomized in our trial and none had developed Kaposi sarcoma.
We communicated these findings and considerations to the
PredART trial data safety and monitoring board (DSMB), which
advised that the PredART trial should continue but that we
should add extra visits for safety assesments. We added one
visit at week 28 and a telephonic follow-up at one year to
ascertain HIV-related cancers. During the week 28 visit, patient
history is taken and clinical examination is performed
specifically to assess for any history, symptoms, or signs of
cancer. One year after starting ART, participants are phoned by
the study team and their clinical records are assessed to review
if there has been a new diagnosis of cancer subsequent to the
week 28 visit. The protocol was amended accordingly and the
information given during the informed consent process was
updated with approval by the relevant ethics committees. The
additional assessments applied to all participants, including
those who had already completed their 12-week follow-up at
the time of this protocol change.
Management of Tuberculosis-Associated Immune
Reconstitution Inflammatory Syndrome
TB-IRIS is a diagnosis of exclusion. When TB-IRIS is
suspected, investigations are performed with the main aim to
exclude alternative causes of clinical deterioration. For all
participants with suspected TB-IRIS, these include the laboratory
investigations listed in Table 1, a bacterial blood culture, and a
chest radiograph. Other investigations (eg, abdominal
ultrasound, lumbar puncture) are undertaken when appropriate
based on clinical presentation. Adherence to ART and TB
treatment is assessed. If TB-IRIS is diagnosed (fulfilling the
INSHI criteria [31]), the study drug is stopped, and open label
prednisone is started at a dose of 1.5 mg/kg/day and weaned
over 4 weeks or longer depending on clinical response.
Other Aspects of Clinical Management
Mild drug rashes are closely monitored with symptomatic
therapy. If more severe drug rashes occur, potential causative
drugs (TB medication, EFV, co-trimoxazole) are stopped and
rechallenge occurs following local guidelines. All other clinical
management, including treatment of new opportunistic
infections, malignancies, and comorbidities, is according to
South African National Department of Health guidelines.
Health-Related Quality of Life Assessments
Health-related quality of life (HR-QOL) is measured using three
different questionnaires: the Patient-Reported Outcomes Quality
of Life–HIV (PROQOL-HIV) [32], an adaptation of the HIV
symptom index by Justice [33], and the more generic EuroQol
Five Dimensions Questionnaire (EQ-5D-3L) [34]. Participants
complete all three questionnaires at week 0, week 4, and week
12. Our aim is to assess HR-QOL in patients with
HIV-associated TB who have recently started treatment for both
conditions and to find which questionnaire best captures their
HR-QOL in the acute phase of their illness. Since the
PROQOL-HIV has not been used in populations with TB-IRIS
in comparable settings, these data will serve to validate this
instrument through triangulating the results of debriefing
interviews and the two other HR-QOL instruments. Moreover,
we are assessing the impact of TB-IRIS and prednisone use on
HR-QOL.
Tuberculosis-Associated Immune Reconstitution
Inflammatory Syndrome Endpoint Evaluation
An endpoint review committee has been established to review
all cases of suspected TB-IRIS and determine whether they
fulfill the INSHI case definition. This committee is comprised
of 3 expert clinical investigators not active at the clinical site.
Reviewers will have access to all clinical and laboratory data
entered in the database, including chest radiographs and TB-IRIS
narrative summaries written by the attending clinician, and they
will be blinded to treatment allocation. The review will take
place after completion of the clinical trial. Each reviewer will
independently review the summaries and data submitted to him
or her, using the INSHI paradoxical TB-IRIS case definition
[31]. For those cases where there is disagreement, consensus
will be sought at a meeting where investigators will also be
present to provide additional clinical information when needed.
If consensus cannot be reached a 2-1 vote will decide.
Statistical Analysis
The statistical analysis of the trial will be performed according
to a plan prespecified before the database is locked and
allocation unblinded. The primary analysis and secondary
efficacy analysis will be performed using an intention-to-treat
approach; safety analysis will be performed using the
all-patients-treated approach. The primary endpoint will be
tested comparing the proportion of patients diagnosed with
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paradoxical TB-IRIS among treatment groups using a Fisher
exact test. Secondary endpoints will be analyzed comparing
study arms with the Fisher exact test (for categorical data) or
Wilcoxon rank-sum test (for continuous data). Time to event
analysis will be used to compare time from the start of ART to
TB-IRIS between study arms. A prespecified subgroup analysis
of those patients with a baseline CD4 count <50/μL will be
performed. Adverse events will be coded following the Medical
Dictionary for Regulatory Activities (MedDRA). Safety
endpoints will be compared between both arms individually
(eg, analysis comparing development of hyperglycemia in each
arm) as well as collectively (eg, analysis comparing all
corticosteroid side effects that occurred in each arm).
Data Handling and Record Keeping
The identity and information of trial participants is kept
confidential. All relevant clinical information to reconstruct and
evaluate the trial is kept as source documents. Data from source
documents are entered into a Web-based electronic database
specifically developed for the trial. The database is
access-controlled and data deidentified. Point-of-entry data
validation and a double–data entry system with discrepancy
reporting are key measures to ensure data integrity. After
completion of the first 12 weeks of the study, the electronic
record of each participant is reviewed against the case report
form. After completion hereof, aggregate database entries are
checked for outlying data, missing data, and systematic errors
according to the prespecified data management plan.
Monitoring, Oversight, and Reporting
The trial is sponsored by the University of Cape Town. which
has subcontracted an independent clinical trial monitor who
conducts monitoring visits once every 1 to 2 months and reports
to the sponsor. An independent DSMB reviewed study
recruitment, data quality, and safety endpoints twice during the
trial—after 80 participants had completed their week 12 visit
and again after 160 participants had completed their week 12
visit. The DSMB was constituted and conducted its tasks
according to the study-specific DSMB charter. It was required
to advise the sponsor of any major safety and data quality issues.
At both interim reviews, the DSMB advised that trial recruitment
and follow-up should continue. All adverse study drug reactions,
serious adverse events, and deaths are reported to the sponsor,
the University of Cape Town Human Research Ethics
Committee, the Institute for Tropical Medicine Institutional
Review Board, and the Medicines Control Council according
to their respective reporting guidelines.
Ethical Approval
The protocol was approved by the University of Cape Town
Human Research Ethics Committee (HREC 136/2013), Institute
of Tropical Medicine Institutional Review Board (882/13), and
the Antwerp University Hospital Ethical Committee (13/20/224).
The same approval schedule is applicable to protocol
amendments. The trial is conducted according to International
Council for Harmonisation Good Clinical Practice standards
[40], the South African Good Clinical Practice guidelines [41],
and the Declaration of Helsinki [42].
Funding
This trial is funded by the European and Developing Countries
Clinical Trials Partnership through a Strategic Primer Grant
(SP.2011.41304.074) that was awarded to the University of
Cape Town, the Institute of Tropical Medicine, and Imperial
College London. There is cofunding from the South African
Government Department of Science and Technology, the
Wellcome Trust (098316, 084323, 104803), the Medical
Research Council of South Africa, and a PhD fellowship from
the Institute for Tropical Medicine.
Results
The trial started enrollment at the end of August 2013; 240
participants are currently enrolled according to plan. Follow-up
for the first 12 weeks was completed in June 2016, and the final
safety assessments for the trial will be completed by March
2017.
Discussion
With guidelines advising that ART be started with minimal
delay during treatment for HIV-associated TB, and many
patients still presenting with a low CD4 count, TB-IRIS will
remain a major complicating factor in patients with
HIV-associated TB starting ART in sub-Saharan Africa. If
corticosteroids are shown to reduce the risk of TB-IRIS without
safety concerns, clinicians will have an evidence-based
preventive option in patients at high risk for TB-IRIS provided
they do not have a contraindication for corticosteroids.
Therefore, we anticipate that the findings of this clinical trial
could inform clinical practice and guidelines in sub-Saharan
Africa and internationally.
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ART: antiretroviral therapy
CrAg: cryptococcal antigen
CRP: C-reactive protein
DSMB: data safety and monitoring board
DST: drug sensitivity testing
EFV: efavirenz
EMB: ethambutol
EQ-5D-3L: EuroQol Five Dimensions Questionnaire
FTC: emtricitabine
HBsAg: hepatitis B surface antigen
HR-QOL: health-related quality of life
ICF: informed consent form
IMPI: Investigation of the Management of Pericarditis
INH: isoniazid
INSHI: International Network for the Study of HIV-associated IRIS
LPV/r: lopinavir boosted with ritonavir
PROQOL-HIV: Patient-Reported Outcomes Quality of Life–HIV
PZA: pyrazinamide
RIF: rifampicin
TB: tuberculosis
TB-IRIS: tuberculosis-associated immune reconstitution inflammatory syndrome
TDF: tenofovir
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